Free Trial

Beam Therapeutics (BEAM) Competitors

Beam Therapeutics logo
$20.02 +0.14 (+0.70%)
Closing price 07/3/2025 03:12 PM Eastern
Extended Trading
$20.19 +0.17 (+0.84%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BEAM vs. CRSP, DNLI, EDIT, NTLA, TWST, VCYT, VERV, LEGN, GRFS, and TGTX

Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Twist Bioscience (TWST), Veracyte (VCYT), Verve Therapeutics (VERV), Legend Biotech (LEGN), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector.

Beam Therapeutics vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Beam Therapeutics (NASDAQ:BEAM) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

CRISPR Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

CRISPR Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$37.31M120.72-$366.25M-$4.52-11.54
Beam Therapeutics$63.52M31.69-$376.74M-$4.61-4.34

In the previous week, CRISPR Therapeutics had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.69 beat CRISPR Therapeutics' score of 0.52 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CRISPR Therapeutics currently has a consensus target price of $71.75, indicating a potential upside of 37.57%. Beam Therapeutics has a consensus target price of $48.75, indicating a potential upside of 143.51%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53
Beam Therapeutics
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Beam Therapeutics has a net margin of -609.24% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,023.64% -20.08% -17.13%
Beam Therapeutics -609.24%-44.24%-30.97%

Summary

Beam Therapeutics beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BEAM vs. The Competition

MetricBeam TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.01B$2.92B$5.55B$9.05B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-4.347.9419.5920.21
Price / Sales31.69281.76418.25119.02
Price / CashN/A42.7336.8958.10
Price / Book2.267.518.035.67
Net Income-$376.74M-$55.14M$3.18B$249.21M
7 Day Performance19.17%4.61%2.93%3.28%
1 Month Performance17.76%4.72%3.75%5.55%
1 Year Performance-13.26%5.92%35.20%21.09%

Beam Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BEAM
Beam Therapeutics
2.5245 of 5 stars
$20.02
+0.7%
$48.75
+143.5%
-14.7%$2.01B$63.52M-4.34510
CRSP
CRISPR Therapeutics
3.0197 of 5 stars
$48.64
+2.4%
$71.75
+47.5%
-3.2%$4.20B$35M-10.76473High Trading Volume
DNLI
Denali Therapeutics
4.6377 of 5 stars
$13.99
-0.8%
$33.71
+141.0%
-31.0%$2.03BN/A-5.24430Positive News
EDIT
Editas Medicine
4.2085 of 5 stars
$2.20
-3.5%
$4.70
+113.6%
-44.5%$184.17M$35.84M-0.72230
NTLA
Intellia Therapeutics
4.7207 of 5 stars
$9.38
-1.9%
$33.37
+255.7%
-53.3%$971.61M$45.57M-1.79600News Coverage
TWST
Twist Bioscience
4.4703 of 5 stars
$36.79
+2.4%
$50.40
+37.0%
-20.6%$2.20B$312.97M-11.32990
VCYT
Veracyte
3.6105 of 5 stars
$27.03
-1.3%
$40.90
+51.3%
+28.1%$2.12B$463.39M65.93790
VERV
Verve Therapeutics
3.4337 of 5 stars
$11.23
-0.6%
$14.57
+29.8%
+118.4%$1.00B$32.33M-5.32110
LEGN
Legend Biotech
3.1081 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-23.0%$6.52B$627.24M-60.152,609Analyst Forecast
GRFS
Grifols
4.332 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+36.7%$6.22B$7.81B7.7323,822
TGTX
TG Therapeutics
3.3061 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+98.0%$5.71B$386.39M149.96290

Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners